CIBC Asset Management
MRNA icon

CIBC Asset Management’s Moderna MRNA Stock Holding History

CIBC Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.52M Buy
78,815
+289
+0.4% +$15K 0.01% 499
2026
Q1 		$3.99M Buy
78,526
+369
+0.5% +$17.2K 0.01% 535
2025
Q4 		$2.3M Buy
78,157
+29,938
+62% +$813K 0.01% 622
2025
Q3 		$1.25M Buy
48,219
+61
+0.1% +$1.7K ﹤0.01% 647
2025
Q2 		$1.33M Sell
48,158
-4,180
-8% -$110K ﹤0.01% 628
2025
Q1 		$1.48M Sell
52,338
-566
-1% -$20.1K ﹤0.01% 622
2024
Q4 		$2.2M Sell
52,904
-60,918
-54% -$2.91M 0.01% 564
2024
Q3 		$7.61M Buy
113,822
+6,794
+6% +$624K 0.02% 330
2024
Q2 		$12.7M Buy
107,028
+1,257
+1% +$159K 0.05% 222
2024
Q1 		$11.3M Buy
105,771
+6,039
+6% +$609K 0.04% 253
2023
Q4 		$9.92M Buy
99,732
+626
+0.6% +$52.7K 0.04% 258
2023
Q3 		$10.2M Buy
99,106
+9,493
+11% +$1.06M 0.04% 231
2023
Q2 		$10.9M Sell
89,613
-545
-0.6% -$72.7K 0.04% 225
2023
Q1 		$13.8M Sell
90,158
-1,007
-1% -$166K 0.05% 196
2022
Q4 		$16.4M Sell
91,165
-2,121
-2% -$347K 0.07% 175
2022
Q3 		$11M Buy
93,286
+2,753
+3% +$418K 0.05% 209
2022
Q2 		$12.9M Buy
90,533
+494
+0.5% +$70.6K 0.05% 188
2022
Q1 		$15.5M Sell
90,039
-568
-0.6% -$95.6K 0.05% 184
2021
Q4 		$23M Buy
90,607
+7,651
+9% +$2.24M 0.08% 144
2021
Q3 		$31.9M Buy
82,956
+30,443
+58% +$11.2M 0.13% 115
2021
Q2 		$12.3M Buy
52,513
+1,990
+4% +$356K 0.05% 202
2021
Q1 		$6.62M Buy
50,523
+7,222
+17% +$1.05M 0.03% 292
2020
Q4 		$4.52M Buy
43,301
+4,215
+11% +$426K 0.02% 327
2020
Q3 		$2.77M Buy
39,086
+26,903
+221% +$1.88M 0.01% 366
2020
Q2 		$782K Hold
12,183
– – ﹤0.01% 605
2020
Q1 		$365K Hold
12,183
– – ﹤0.01% 691
2019
Q4 		$238K Buy
+12,183
New +$216K ﹤0.01% 980

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

CIBC Asset Management's MRNA Position: Q2 2026 in Review

CIBC Asset Management increased its Moderna (MRNA) stake by 0.37% in Q2 2026, buying an estimated $15K and bringing the position to 78,815 shares worth $5.52M. The position accounts for 0.01% of the portfolio, ranked #499.

CIBC Asset Management first reported a position in MRNA in Q4 2019 and has held it in 27 quarters since. The position peaked at $31.9M in Q3 2021. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • CIBC Asset Management held 78,815 shares of Moderna worth $5.52M as of Q2 2026.
  • CIBC Asset Management bought 289 Moderna shares in Q2 2026, an estimated $15K.
  • Moderna made up 0.01% of CIBC Asset Management's portfolio in Q2 2026, its #499 holding.
  • CIBC Asset Management first reported a position in Moderna in Q4 2019 and has held it in 27 quarters since.
  • CIBC Asset Management's Moderna position peaked at $31.9M in Q3 2021.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.